RxDoctor Payments Data

Megan McQuarrie, MD

Sports Medicine · Ocean City, NJNPI 1932605581

Payments from drug & device makers

$1,932in general payments, 2019–2025

Across 117 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$610
  • Novo Nordisk$344
  • Amgen$248
  • Pfizer$122
  • AstraZeneca$107
  • Lilly USA, LLC$76
  • plus $424 from 16 others

What the payments were for

  • Food & beverage$1,88798%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,932 in reported general payments places this provider in the 55th percentile of 221 sports medicine providers in New Jersey.

See all sports medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$211,342
Medicare patients
513
Services billed
2,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$105,176
EliquisApixaban106$89,468
RybelsusSemaglutide37$51,899
FarxigaDapagliflozin Propanediol30$33,782
XareltoRivaroxaban34$33,452
JanuviaSitagliptin Phosphate28$30,741
JardianceEmpagliflozin31$28,400
Repatha SureclickEvolocumab25$22,439
MyrbetriqMirabegron17$19,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,378
VraylarCariprazine Hcl12$16,824
EntrestoSacubitril/Valsartan18$15,937
Praluent PenAlirocumab18$14,467
MounjaroTirzepatide12$11,862
Bydureon BciseExenatide Microspheres12$9,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$344$157,075127 claims
PfizerEliquis, Paxlovid$122$90,897122 claims
AstraZenecaFarxiga$107$33,78230 claims
Johnson & JohnsonXarelto$15$33,45234 claims
Boehringer IngelheimJardiance$14$28,40031 claims
GSKTrelegy Ellipta, Breo Ellipta$15$24,73242 claims
AbbVieVraylar, Synthroid$610$22,56083 claims
Astellas Pharma US IncMyrbetriq$16$19,78917 claims
Lilly USA, LLCMounjaro$76$11,86212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 221 sports medicine providers in New Jersey.

Other sports medicine in Ocean City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →